L-Arginine-stabilized Semaglutide dissolving microneedles achieve robust transdermal delivery and mechanical strength
Background
The management of Type 2 Diabetes and Obesity has been revolutionized by GLP-1 receptor agonists like Semaglutide. However, their clinical utility is often hampered by low oral bioavailability, necessitating frequent injections that can lead to patient discomfort and poor adherence. This creates a significant gap for alternative, patient-friendly delivery methods. Transdermal delivery via dissolving microneedles (DMNs) offers a promising solution, bypassing gastrointestinal degradation and avoiding injections, but maintaining peptide integrity and stability within the DMN matrix remains a key challenge.
Study Design
Researchers developed novel dissolving microneedle (DMN) arrays for transdermal Semaglutide delivery. The DMNs were formulated using a polymeric blend of hyaluronic acid, PETOX, and L-arginine, with L-arginine specifically incorporated to enhance peptide integrity and stability. The study comprehensively characterized these SMG-DMNs through various methods, including mechanical strength testing, ex-vivo porcine skin insertion studies, and an agarose-based dissolution model to optimize the polymeric matrix. Scanning electron microscopy and confocal microscopy were used for structural analysis, while fluorescence imaging verified transdermal deposition and penetration efficiency.
Results
The developed Semaglutide-loaded dissolving microneedles (SMG-DMNs) demonstrated excellent physical and functional properties. They exhibited robust mechanical strength, with a fracture force of 3.47 N/needle, ensuring effective skin penetration. Insertion studies using Parafilm M® showed excellent insertion capabilities, with >50% penetration at a 450 µm depth. The optimized polymeric matrix, incorporating L-arginine, facilitated sustained drug release over 12 hours, indicating potential for prolonged therapeutic effects. The agarose-based dissolution model confirmed efficient dissolution and drug release from the matrix. >Fluorescence imaging further verified efficient transdermal deposition and penetration of a dye, strongly suggesting successful transdermal delivery of Semaglutide upon insertion, addressing a critical barrier to peptide stability and delivery.
Key Findings
- Semaglutide DMNs achieved robust mechanical strength of 3.47 N/needle (fracture force).
- DMNs demonstrated >50% insertion at 450 µm depth in
Parafilm M®. - The L-arginine-based DMN formulation enabled sustained Semaglutide release over 12 hours.
- Fluorescence imaging confirmed efficient transdermal deposition and penetration of a model dye.
Why It Matters
This research presents a significant step towards a patient-friendly, non-injectable alternative for Semaglutide delivery, potentially transforming adherence and outcomes for individuals managing Type 2 Diabetes and Obesity. By enhancing peptide stability with L-arginine and enabling sustained transdermal release, this DMN system could drastically improve patient comfort and compliance compared to current injectable formulations. While currently preclinical, the successful ex-vivo demonstration of robust mechanical strength, efficient insertion, and prolonged release lays the groundwork for future in-vivo studies. This technology could pave the way for novel GLP-1 receptor agonist protocols, making these life-changing therapies more accessible and less burdensome for millions.
semaglutide
transdermal-delivery
microneedles
l-arginine
diabetes
obesity